Claims for Patent: 9,506,924
✉ Email this page to a colleague
Summary for Patent: 9,506,924
Title: | Compositions and methods for characterizing a myopathy |
Abstract: | The invention provides compositions, methods, and kits for diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample. |
Inventor(s): | Casciola-Rosen; Livia A. (Pikesville, MD), Christopher-Stine; Lisa (Baltimore, MD), Mammen; Andrew (Baltimore, MD), Rosen; Antony (Pikesville, MD) |
Assignee: | The Johns Hopkins University (Baltimore, MD) |
Application Number: | 15/143,728 |
Patent Claims: | 1. A method for treating an autoimmune-mediated myopathy in a subject, the method comprising: detecting an autoimmune response in the subject by detecting an autoantibody
that recognizes a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) protein; and administering to the subject an immunosuppressive agent to thereby treat the autoimmune-mediated myopathy.
2. The method of claim 1, wherein the immunosuppressant agent is a member selected from the group consisting of a glucocorticoid, a cytostatic agent, and a drug acting on immunophilins. 3. The method of claim 2, wherein the glucocorticoid is prednisone. 4. The method of claim 2, wherein the cytostatic agent is a member selected from the group consisting of azathioprine and methotrexate. 5. The method of claim 2, wherein the drug acting on immunophilins is a member selected from the group consisting of cyclosporine and tacrolimus. 6. The method of claim 2, wherein the immunosuppressant is a member selected from the group consisting of hydroxychloroquine, intravenous immunoglobulin, mycophenylate mofetil, and rituximab. 7. The method of claim 1, wherein the myopathy is an autoimmune-mediated myopathy is associated with statin therapy. 8. The method of claim 1, wherein the HMGCR protein is the full length protein or a fragment thereof having HMGCR antibody binding activity. 9. The method of claim 8, wherein the HMGCR protein fragment comprises amino acids 340-888 of the HMGCR protein. 10. A method for treating an autoimmune-mediated myopathy in a subject, the method comprising: administering to the subject an immunosuppressive agent to treat the autoimmune-mediated myopathy, wherein an autoantibody that recognizes a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) protein has been detected from said subject. 11. The method of claim 10, wherein the immunosuppressant agent is a member selected from the group consisting of a glucocorticoid, a cytostatic agent, and a drug acting on immunophilins. 12. The method of claim 11, wherein the glucocorticoid is prednisone. 13. The method of claim 11, wherein the cytostatic agent is a member selected from the group consisting of azathioprine and methotrexate. 14. The method of claim 11, wherein the drug acting on immunophilins is a member selected from the group consisting of cyclosporine and tacrolimus. 15. The method of claim 11, wherein the immunosuppressant is a member selected from the group consisting of hydroxychloroquine, intravenous immunoglobulin, mycophenylate mofetil, and rituximab. 16. The method of claim 10, wherein the myopathy is an autoimmune-mediated myopathy is associated with statin therapy. 17. The method of claim 10, wherein the HMGCR protein is the full length protein or a fragment thereof having HMGCR antibody binding activity. 18. The method of claim 17, wherein the HMGCR protein fragment comprises amino acids 340-888 of the HMGCR protein. |
Details for Patent 9,506,924
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-04-16 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-04-16 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2030-04-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.